Aton: Subsidiary Inoviem Launches Two Preclinical Programs with Biopharma Partners
Aton Group, specializing in life sciences and medical technologies, reports on the operational progress of its subsidiary Inoviem Scientific, which is engaged in translational pharmacology. This update details the deployment of its integrated platform with biopharmaceutical partners.
Innovative Integrated Platform Developed by Inoviem Scientific
Inoviem Scientific has developed an integrated platform that combines proprietary technologies for sampling and analyzing biological samples with services for molecular characterization assisted by artificial intelligence. This platform supports its partners throughout the drug development cycle, from basic research to medical decision support in hospitals, through diagnostic solutions and therapeutic guidance. The model positions the patient sample as the common thread at each stage, offering a departure from conventional pharmaceutical development models.
Pioneering Preclinical Programs in Partnership with Biopharmaceutical Entities
Two pioneering preclinical programs are conducted in partnership with biopharmaceutical players. Thanks to its proprietary technologies, Inoviem Scientific performs functional analysis of new drug candidates directly on patient samples, ahead of clinical trials. This approach allows its partners to access data generated from real patients within reduced timelines, while preserving the integrity and spatial anatomy of the samples. Concurrently, Inoviem Scientific continues to optimize its operational and analytical capabilities to meet the sustained demand for more predictive and physiologically relevant preclinical models.
